Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1
Authors: Mathilde Renaud, Maria-Céu Moreira, Bondo Ben Monga, Diana Rodriguez, Rabab Debs, Perrine Charles, Malika Chaouch, Farida Ferrat, Chloé Laurencin, Laurent Vercueil, Martial Mallaret, Abderrahim M’Zahem, Lamia Ali Pacha, Meriem Tazir, Caroline Tilikete, Elisabeth Ollagnon, François Ochsner, Thierry Kuntzer, Hans H. Jung, Jean-Marie Beis, Jean-Claude Netter, Atbin Djamshidian, Mattew Bower, Armand Bottani, Richard Walsh, Sinead Murphy, Thomas Reiley, Éric Bieth, Filip Roelens, Bwee Tien Poll-The, Charles Marques Lourenço, Laura Bannach Jardim, Rachel Straussberg, Pierre Landrieu, Emmanuel Roze, Stéphane Thobois, Jean Pouget, Claire Guissart, Cyril Goizet, Alexandra Dürr, Christine Tranchant, Michel Koenig, Mathieu Anheim
Journal: JAMA Neurology (2018)

<h3>Importance</h3> Ataxia with oculomotor apraxia type 1 (AOA1) is an autosomal recessive cerebellar ataxia due to mutations in the aprataxin gene (<i>APTX</i>) that is characterized by early-onset cerebellar ataxia, oculomotor apraxia, axonal motor neuropathy, and eventual decrease of albumin serum levels. <h3>Objectives</h3> To improve the clinical, biomarker, and molecular delineation of AOA1 and provide genotype-phenotype correlations. <h3>Design, Setting, and Participants</h3> This retrospective analysis included the clinical, biological (especially regarding biomarkers of the disease), electrophysiologic, imaging, and molecular data of all patients consecutively diagnosed with AOA1 in a single genetics laboratory from January 1, 2002, through December 31, 2014. Data were analyzed from January 1, 2015, through January 31, 2016. <h3>Main Outcomes and Measures</h3> The clinical, biological, and molecular spectrum of AOA1 and genotype-phenotype correlations. <h3>Results</h3> The diagnosis of AOA1 was confirmed in 80 patients (46 men [58%] and 34 women [42%]; mean [SD] age at onset, 7.7 [7.4] years) from 51 families, including 57 new (with 8 new mutations) and 23 previously described patients. Elevated levels of α-fetoprotein (AFP) were found in 33 patients (41%); hypoalbuminemia, in 50 (63%). Median AFP level was higher in patients with AOA1 (6.0 ng/mL; range, 1.1-17.0 ng/mL) than in patients without ataxia (3.4 ng/mL; range, 0.8-17.2 ng/mL;<i>P</i> &lt; .01). Decreased albumin levels (ρ = −0.532) and elevated AFP levels (ρ = 0.637) were correlated with disease duration. The p.Trp279* mutation, initially reported as restricted to the Portuguese founder haplotype, was discovered in 53 patients with AOA1 (66%) with broad white racial origins. Oculomotor apraxia was found in 49 patients (61%); polyneuropathy, in 74 (93%); and cerebellar atrophy, in 78 (98%). Oculomotor apraxia correlated with the severity of ataxia and mutation type, being more frequent with deletion or truncating mutations (83%) than with presence of at least 1 missense variant (17%;<i>P</i> &lt; .01). Mean (SD) age at onset was higher for patients with at least 1 missense mutation (17.7 [11.4] vs 5.2 [2.6] years;<i>P</i> &lt; .001). <h3>Conclusions and Relevance</h3> The AFP level, slightly elevated in a substantial fraction of patients, may constitute a new biomarker for AOA1. Oculomotor apraxia may be an optional finding in AOA1 and correlates with more severe disease. The p.Trp279* mutation is the most frequent<i>APTX</i>mutation in the white population.<i>APTX</i>missense mutations may be associated with a milder phenotype.